KTTA

Pasithea Therapeutics Corp. (KTTA) is a biopharmaceutical company headquartered in Miami Beach, specializing in groundbreaking therapies for psychiatric and neurological disorders utilizing psychedelic compounds. Focused on addressing critical unmet medical needs, the company is strategically positioned to capitalize on the expanding mental health treatment market. With a strong emphasis on clinical research and innovation, Pasithea's proprietary platform is designed to improve patient outcomes and suggests significant potential for sustainable growth and value creation within the healthcare sector. As it advances its clinical programs, Pasithea is well-positioned to make substantial contributions to the evolving landscape of mental health solutions.